February 10, 2022
SEATTLE – February 10, 2022 – FLG client Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, has announced the closing of a $60 million Series A financing round. FLG partner Greg Curhan assisted as CFO. The round will be used for funding topline data from the company’s Phase 2b clinical trial of CRV-101, a new vaccine for shingles. The financing was led by RA Capital Management and joined by Adjuvant Capital, Janus Henderson Investors, EN Investment, and founding investor GC Pharma.
The full press release is here.